Abstract:Background: Anemia is highly prevalent in patients with peripheral vascular disease and has been associated with postoperative cardiac events and mortality and adverse limb events after revascularization procedures. Allogenic blood transfusions have also been associated with adverse events including hospital-acquired infections, cardiac morbidity, and reduced survival. The aim of this study was to evaluate the impact of blood transfusion on major adverse cardiac events (MACE) and major adverse limb events (MALE) in patients undergoing infrainguinal lower extremity bypass (LEB) operations. Methods: We performed a retrospective cohort analysis of patients undergoing infrainguinal LEB in the Society for Vascular Surgery Vascular Quality Initiative database between 2003 and 2020. Patients were first grouped by their preoperative hemoglobin (Hgb) number (severe anemia: Hgb 7-10 g/dL; moderate anemia: 10-12 g/dL; normal Hgb: >12 g/dL) and then stratified by their transfusion status (perioperative transfusion versus no perioperative transfusion). Primary end points were MACE, defined as myocardial infarction, new congestive heart failure, dysrhythmia, or stroke in the postoperative period, and MALE, defined as return to operating room for thrombosis, loss of primary patency on follow-up, and major ipsilateral amputation on follow-up. Secondary outcomes included wound complications, graft infections, 30-day mortality, and 1-year survival. Outcomes were compared between patients who received transfusions and those who did not at every anemic threshold. Multivariable logistic regression was performed to evaluate the impact of blood transfusion on primary outcomes. Results: A total of 55,884 patients were included for analysis, of which 16.3% had severe anemia, 25.9% had moderate anemia, and 57.8% had normal Hgb. Anemia severity was associated with increased rates of MACE (9.8% vs. 8.3% vs. 5.2%, P < 0.0001) and MALE (32.2% vs. 24.8% vs. 18.6%, P < 0.0001). On univariate analysis, transfusion was consistently associated with increased rates of MACE and MALE at every anemic threshold (P < 0.0001 for all). Transfusion was also associated with increased rates of 30-day mortality at all anemic thresholds (P < 0.0001 for all) and reduced 1-year survival at all anemic thresholds (log-rank P < 0.0001 for all). On multivariable analysis for MACE, an interaction factor was observed between preoperative Hgb and transfusion status (P < 0.0001). At every anemic threshold, transfusion was independently associated with MACE (severe: odds ratio [OR] 2.4 [95% confidence interval [CI]: 2.0-2.9]; moderate: OR 2.8 [95% CI: 2.5-3.2]; normal: OR 4.5 [95% CI: 4.0-5.0]). On multivariable analysis for MALE, an interaction factor was also observed between preoperative Hgb and transfusion status (P < 0.0001). At every anemic threshold, transfusion was independently associated with MALE (severe: OR 2.1 [95% CI: 1.9-2.3]; moderate: OR 1.8 [95% CI: 1.7-2.0]; normal: OR 2.6 [95% CI: 2.4-2.8]). Conclusions: Perioperative blood transfusion in patients undergoing infrainguinal LEB is independently associated with MACE and MALE in all patients with preoperative Hgb >7 g/dL. Despite the morbidities associated with anemia, these findings highlight that transfusion may not be the optimal treatment modality, particularly in patients with higher preoperative Hgb. Future research is needed to define the transfusion threshold in this population.

Anemia or Transfusion: Getting to the Heart of the Issue

Transfusion in the critically ill: does it affect outcome?

Impact of peri-operative red blood cell transfusions for treatment of anemia on acute rejection in renal transplant recipients

Preoperative Anemia and Postoperative Outcomes in Cardiac Surgery: A Mediation Analysis Evaluating Intraoperative Transfusion Exposures

Risks, benefits, alternatives and indications of allogenic blood transfusions

Factors Associated with Red Blood Cell Transfusion among Hospitalized Patients: a Cross-Sectional Study.

The Impact of Blood Conservation on Outcomes in Cardiac Surgery: Is It Safe and Effective?

Transfusion in Anemic Patients with Acute Coronary Syndromes: A Population-Based Cohort Study

Red Blood Cell Transfusion Strategies in Cardiovascular Interventions

Anemia and red blood cell transfusion in neurocritical care

Transfusion targets and adverse events in pediatric perioperative acute Anemia

Association of Anemia and Transfusion with Major Adverse Cardiac Events and Major Adverse Limb Events in Patients Undergoing Open Infrainguinal Bypass

Anemia Tolerance Versus Blood Transfusion on Long-Term Outcomes after Colorectal Cancer Surgery: A Retrospective Propensity-Score-matched Analysis

An Analysis of Anemia, Transfusions and CABG Outcomes in the National STS Database

Red blood cell transfusion in neurosurgical patients

Perioperative blood transfusion and outcome

Anemia and Red Blood Cell Transfusion in Aneurysmal Subarachnoid Hemorrhage

Number and Type of Blood Products Are Negatively Associated With Outcomes After Cardiac Surgery

Contemporary Risk Factors and Outcomes of Transfusion-Associated Circulatory Overload

Restrictive and liberal red cell transfusion strategies in adult patients: reconciling clinical data with best practice

Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding